Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
25 mg orally once daily in a two-year randomized study
The trial measured growth hormone, IGF-1 and body composition; it did not authorise anti-ageing use.
View source25 mg orally once daily for 12 months
The large randomized trial did not slow clinical progression.
View sourceReference charts and a podcast summary describe an oral 25 mg capsule once daily, with a wider practice range of 10-25 mg cited; one paraphrase mentions a subcutaneous figure that is inconsistent with the oral route and is not carried forward
Forum provenance from an authenticated archive with usernames omitted. No individual member logged a personal MK-677 dose, so these are reference-chart and summary figures rather than a member protocol; MK-677 is an oral small molecule and no injectable schedule is established.
View sourceEvidence summary
An oral, non-peptide ghrelin receptor agonist studied in several controlled trials. It is investigational and has no injectable formulation.
Protocol basis
The protocol summary uses oral human trials and makes clear that trial quantities and surrogate hormone changes do not create an injectable or wellness protocol.
What remains uncertain
An approved indication, durable clinical benefit and a favourable long-term benefit-risk balance remain unestablished.
Community provenance (Peppys)
An authenticated research-forum archive carries no member-authored MK-677 dosing log; the compound is oral, and the figures come from general reference charts and a growth-hormone-peptide podcast summary rather than a personal protocol. Those describe an oral 25 mg capsule once daily, with a wider practice range of 10-25 mg cited, and flag intense hunger and water retention as trade-offs. One paraphrase records a subcutaneous figure that is inconsistent with the oral route; it is transcribed for completeness but not carried forward. Usernames and post numbers are omitted and the figures are logged as community provenance without endorsement. No community dose planner is shown because MK-677 is an oral small molecule, not a reconstituted injectable.
Online research community archive check
The archive identifies MK-677 as an oral small molecule and discusses hunger and water retention, but it provides no clean community schedule. A quoted topical product composition is not promoted to a protocol (raw/peptide-education/pe-ipamorelin.md:1688-1692).